Market Overview:
INAAT refers to gene amplification method used for molecular diagnostics with a constant temperature requirement. Unlike Polymerase Chain Reaction (PCR) which requires temperature cycling, INAAT works efficiently at a single temperature. Some common INAAT methods used are Loop-mediated isothermal amplification (LAMP), transcription mediated amplification (TMA), helicase-dependent amplification (HDA), nucleic acid sequence-based amplification (NASBA), and others. It is primarily used for rapid diagnosis of infectious diseases like HIV, tuberculosis, influenza etc. It provides results 10-100 times faster than PCR with high sensitivity and specificity.
Market Dynamics:
The rising prevalence of infectious and genetic diseases is one of the major drivers of the Isothermal Nucleic Acid Amplification Technology (Inaat) Market. As per WHO, tuberculosis kills around 1.6 million people each year making it one of the top 10 causes of death worldwide. Similarly, according to CDC, around 38,000 new cases of HIV are reported each year in the United States. Rapid diagnosis of such diseases helps in early treatment and containment. Secondly, adoption of molecular diagnostics in point-of-care setting over conventional methods is augmenting the demand for INAAT. Its ease of use and rapid results enable quick diagnosis at physician offices and patient bedside without moving samples to centralized labs. This is ideal for emergency response and epidemics.
Segment Analysis
The isothermal nucleic acid amplification technology (INAAT) market is dominated by the molecular diagnostic segment. This segment accounts for over 60% of the total market share owing to higher preference of INAAT in point-of-care testing of infectious diseases like influenza, sepsis, respiratory infections etc. Isothermal amplification methods have emerged as an attractive alternative to PCR as they do not require thermal cycling equipment, thus simplifying diagnostic procedures especially in resource-limited settings.
Pest Analysis
Political: Regulations supporting deployment of rapid diagnostic tests at decentralized locations are expected to drive the adoption of INAAT. Various governments are focusing on strengthening healthcare infrastructures.
Economic: High disease burden of infectious diseases globally is putting economic strain on countries. Easy-to-use and low-cost INAAT provide a cost-effective solution.
Social: Growing public health awareness and increasing healthcare access and expenditure are supporting market growth. There is a rising demand for prompt diagnosis to minimize disease spread.
Technological: Continuous research into developing enhanced, reproducible and multiplexable INAAT methods to detect multiple pathogens simultaneously will further augment the market. Miniaturization of platforms will facilitate point-of-care applicability.
Key Takeaways
The global isothermal nucleic acid amplification technology (INAAT) market size is expected to reach USD 4,242.4 million by 2030 from an estimated USD 2,490.2 million in 2023, exhibiting a CAGR of 8.4% during the forecast period. Increasing incidence of infectious diseases across the globe due to rising elderly population, emerging lifestyle-related disorders, climate change and mutations in pathogen virulence is expected to drive the market.
Regionally, North America dominated the INAAT market historically and is projected to retain its position throughout the forecast period attributed to well-established healthcare systems, widespread awareness about molecular diagnostics and continuous technological advancements in the region. However, Asia Pacific is anticipated to witness highest growth owing to rapidly improving healthcare infrastructure, conducive government policies, and increasing spending power in developing countries like India and China.
Key players operating in the isothermal nucleic acid amplification technology (INAAT) market are Alere Inc., Becton, Dickinson & Company, BioHelix Corporation, BioMerieux Biotechnology Company, Hologic Gene-Probe, QIAGEN Company, Thermo Fisher Scientific, Inc., Lucigen Corporation, Quidel Corporation, and NuGEN. Major players are focusing on new product launches, geographical expansions and acquisitions to strengthen their market presence. For instance, in April 2022, Hologic received emergency use authorization (EUA) for its Aptima SARS-CoV-2 assay to detect the Omicron variant on the company’s fully automated Panther system.
Read More:
https://www.marketwebjournal.com/isothermal-nucleic-acid-amplification-technology-market-demand/
